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Objectives: optimal treatment of carbapenem-resistant Gram-negative (CR-GNB) infections is uncertain due to the 68 
lack of good-quality evidence and the limited effectiveness of available antibiotics.  The aim of this survey was to 69 
investigate clinicians’ prescribing strategies for treating CR-GNB infections worldwide. 70 
Methods: a 36-items-questionnaire was developed addressing the following aspects of antibiotic prescribing: 71 
respondent’s background, diagnostic and therapeutic availability, preferred antibiotic strategies and rationale for 72 
selecting combination therapy.  Prescribers were recruit d following the snowball-sampling approach, and  post-73 
stratification correction with inverse proportional weights was used to adjust the sample’s representativeness. 74 
Results: 1012 respondents from 95 countries participated in the survey. Overall, 298 (30%) of respondents had local 75 
guidelines for treating CR-GNB at their facility and 702 (71%) had access to Infectious Diseases consultation, with 76 
significant discrepancies according to country economic status: 85% (390/502)  in High-Income-Countries vs 59% 77 
(194/283) in Upper-Medium-Income-Countries and 30% (118/196)  in Lower-Middle-Income-Countries/Lower-78 
Income-Countries). Targeted regimens varied widely, ranging from 40 regimens for CR-Acinetobacter spp. to more 79 
than 100 regimens for CR-Enterobacteriaceae. Althoug  the majority of respondents acknowledged the lack of 80 
evidence behind this choice, dual combination was the preferred treatment scheme and carbapenem-polymyxin was 81 
the most prescribed regimen, irrespective of pathogen and infection source. Respondents noticeably disagreed 82 
around the meaning of ‘combination therapy’ with 20% (150/783) indicating the simple addition of multiple 83 
compounds, 42% (321/783) requiring the presence of in vitro activity and 38% (290/783) of in vitro-synergism. 84 
Conclusions: management of CR-GNB infections is far from being standardized. Strategic public health focussed 85 
randomised controlled trials are urgently required to inform evidence-based treatment guidelines.  86 
 87 
 88 
Introduction  89 
In 2017, the World Health Organization (WHO) prioritized carbapenem-resistant Gram-negative bacteria (CR-90 
GNB) Acinetobacter baumannii, Pseudomonas aeruginosa, nd Enterobacteriaceae s species of critical importance 91 
for research and development of new and effective antibiotics. (1)  Only a few new antibiotics with the potential to 92 
treat those bacteria have come to the market, and fewer still are in the later stages of their clinical development.(2) 93 
However, none of these new compounds have been tested in large randomized clinical trials enrolling patients with 94 
CR-GNB infections before their approval. Robust evid nce of their effectiveness and superiority to conventional 95 











mostly observational and limited by small sample size  and the lack of adjustment for major confounders.(3-5) The 97 
few available guidance documents,  although recognizing the low quality of the evidence, suggest that combination 98 
therapy might be superior to monotherapy when dealing severe infections. (6, 7) However, due to the very limited 99 
evidence, it is difficult to provide precise recommendations as to the specific antibiotic combinations that should be 100 
adopted for treating the possible clinical scenarios. In an era where the rational use of the few avail ble antibiotics is 101 
of utmost importance, clinicians treating severe inf ctions caused by CR-GNB have to make decisions on which 102 
antibiotics to use on a daily basis without the support of evidence-based recommendations and heterogene us access 103 
to diagnostic and therapeutic resources.(8) 104 
The main goal of this study was to conduct a cross-sectional survey to assess antibiotic prescribing patterns among 105 
clinicians worldwide with a particular focus on the use of combination therapy. 106 
 107 
Methods 108 
Target population and sampling  109 
The target population of the survey was clinicians managing patients with severe infections caused by CR-GNB in 110 
their current practice (a minimum of 5 cases of anyCR-GNB infection per year was set as a limit to participate in 111 
the survey). Participants were sampled from the targe  population in accordance with the ‘snowball sampling’ 112 
approach, which relies essentially on two key phases: i) the recruitment of a core sample of individuals having 113 
similar characteristics to the population target (a core-expert group of 99 prescribers selected from surveillance 114 
networks and scientific societies) and ii)  the referral process, in which this group nominates, through various 115 
transmission routes, other individuals who meet the eligibility criteria.(9-11) The objective was to involve at least 116 
one representative from all the countries where diagnostic capabilities for detecting carbapenem-resistance are in 117 
place (the full process is detailed in Table S1a-S2).  118 
Survey development, validation and distribution 119 
The survey content was developed and validated in accordance with current guidelines on surveys in medical 120 
research.(12-16) The final questionnaire consisted of 36 open-ended, single and multiple-choice items addressing 121 
four major aspects of antibiotic prescribing: respondent’s background, diagnostic and therapeutic avail bility, 122 
preferred antibiotic strategies and rationale for selecting combination therapy. The questionnaire wasvalidated by 123 
experts from different geographic areas and disseminated via a Survey Monkey link (https://it.surveymonkey.com) 124 
during a 10 week period (the final questionnaire and details of the development and validation process are detailed 125 











Statistical analysis  127 
Anonymous data were automatically entered by the survey software into an electronic database. Both complete and 128 
incomplete questionnaires were included for analysis. Results were expressed as frequency of responses for ach 129 
question or as median with interquartile range (IQR), when appropriate. The number of total responses for each 130 
question item was used as denominator. Responses wer  computed overall or stratified by four subgroups of interest: 131 
WHO region; income category (in accordance with the 2019 World Bank Classification); patients’ age (neo ates: 0-132 
1 month, children: >1 month- 14 years, adults: > 14 years); respondents’ antibiotic prescribing frequency (low rate 133 
prescribers: from 1 to 4 cases per year; medium rate prescribers: from 5 to 20 cases per year, high rate prescribers: 134 
more than 20 cases per year). Between groups comparisons were computed using Chi-square and a two-sided p 135 
value <0⋅05 was regarded as significant. Data were analysed u ing STATA 15 (Statacorp LP, College Station, US). 136 
Figures were created using Python 3.7.3 and Matplotlib package v. 3.2.1. 137 
To address the imbalance due to the non-probabilistic sampling method, a post-stratification correction was applied 138 
for pre-selected question items according to the respondent’s country and hospital. In the post-stratific ion analysis, 139 
the weights were adjusted so that the totals in each group are equal to the known population totals.(17, 18)  140 
 141 
Official submission to the Ethics Committee was deem d unnecessary because the participation into the survey was 142 
voluntary and anonymous.  143 
 144 
Results 145 
Respondents’ characteristics 146 
The survey was disseminated during a 10 week- period, from April 15th until June 28th 2019. In total 1012 147 
respondents from 95 countries and 687 hospitals return d the questionnaire with an average completion rate of 86%. 148 
The distribution of respondents according to the four main categories is shown in Table 1. The majority of 149 
respondents were specialized in Infectious Diseases (548; 54%), were employed in tertiary level hospitals (810; 150 
81%) and in teaching or university affiliated hospitals (859; 85%). The distribution of respondents by country and 151 
specialty is displayed in Table S3 and Figure S2. 152 
Local prevalence of carbapenem resistance in GNB was reported with high variability among countries and among 153 
hospitals within the same country and, in some cases even within the same region. (Table S4). Overall, 20% 154 
(193/974) of respondents did not have data on local phenotypic drug resistance rates; the genotypic mehanism of 155 











of serine-carbapenemases was the most frequent resis ance mechanism in the American Region (93/203; 46%), 157 
while the production of metallo-beta-lactamases wasthe most common resistance mechanism in South East Asia 158 
(39/90; 43%) and Western Pacific Regions (34/77; 44%) (Table S5). 159 
Availability of diagnostics, therapeutics, and treatment guidelines 160 
Availability of antibiotics was heterogeneous across countries and, often, also within the same country. Gentamicin, 161 
trimethoprim-sulfamethoxazole (TMP-SMX), rifampin, amikacin, and carbapenems were available in more than162 
95% of the surveyed countries, regardless of the income. Carbapenems were placed under restrictive policies in 78% 163 
(32/41) of High-Income-Countries; in 89% (25/28) of  Upper-Middle-Income-Countries and in 61% (16/26) of 164 
Lower-Middle-Income-Countries/Lower-Income-Countries. Colistin was available in 83% (79/94) of the surveyed 165 
countries, with restrictive policies in place in 90% (37/41) of HIC, 91% (25/28) of Upper-Middle-Income-Countries 166 
and 77% (20/26) of Lower-Middle-Income-Countries/Lower-Income-Countries. Among the drugs that most recently 167 
entered the market, ceftazidime/avibactam was availble in 33% (32/94) of countries (26/41, 63% High-Income-168 
Countries; 4/28, 14% Upper-Middle-Income-Countries and 2/26, 8% Lower-Middle-Income-Countries/Lower-169 
Income-Countries). Less than 10 respondents had access to the most recently approved antibiotic compounds 170 
(meropenem/vaborbactam, eravacycline and plazomicin). Availability of antibiotics by country and income is 171 
detailed in Figures S3a-c. 172 
Only 30% (298/981) of respondents reported that local guidelines for treating CR-GNB were available, with no 173 
significant difference according to income category (Table S6). Active Infectious Diseases consultation services 174 
were significantly more common among respondents from High-Income-Countries (390/582, 85%) compared to 175 
respondents from Upper-Middle-Income-Countries (194/283, 59%) and Lower-Middle-Income-Countries/Lower-176 
Income-Countries (118/196, 30%) (p <0⋅01). 177 
As for diagnostic resources, 77% (767/908) of respondents had access to standard susceptibility testing at a local 178 
level with no differences according to the income status. More complex diagnostics (MALDI-TOF and NAAT) were 179 
significantly more accessible in High-Income-Countries compared to Upper-Middle-Income-Countries and Lower-180 
Middle-Income-Countries/Lower-Income-Countries (Table 2). As a direct consequence of this variability, the timing 181 
of diagnosis was considerably longer in low-resourced settings, with 23% (110/473) of respondents from those 182 
countries receiving blood cultures more than 72 hours after sampling, compared to only 7% (37/500) in H gh-183 
Income-Countries (Table 3).  184 











Colistin and tigecycline were preferably prescribed in combination by 73% (492/671) and 71% (330/647) of 186 
respondents, followed by combination fosfomycin (53%; 244/463), ceftazidime/avibactam (45%; 145/333), 187 
polymyxin B (35%; 104/297) and gentamicin (34%; 264/770) (Table 4).  188 
As for prescribing strategies, carbapenem loading dose and extended infusion were adopted more frequently by high 189 
rate prescribers compared to clinicians that dealt with CR-GNB infections less frequently. Similarly, higher dose 190 
tigecycline and loading dose of polymyxins and tigecycline, were significantly more frequent in the hig  rate 191 
prescribers group compared with the others (p <0⋅01 for all comparisons; Supplementary Table S7).    192 
The decision to start an empiric coverage for CR-GNB was significantly more common in prescribers from High-193 
Income-Countries and directly associated with patients’ clinical severity. Local epidemiological data and/or 194 
individual risk factors played less of a role in driving the decision to start empiric coverage (Figure 1).  195 
As for targeted therapy, the preferred strategy wasthe combination of two antibiotics (between 35% and 45% of 196 
respondents depending on sepsis sources or bacterial species). The use of single-antibiotic therapy was second in 197 
preference, especially for CR Acinetobacter spp. And CR Pseudomonas spp. (23-37% and 26-35% of respondents, 198 
respectively, depending on the sepsis source). A combination of three antibiotics was regarded as the preferred 199 
strategy by a lower number of respondents (15-20% depending on sepsis sources or pathogen type). Full resu ts on 200 
preferred therapeutic choices are displayed in Tables S8-S10.  201 
When considering the components in the targeted combination regimens, respondents selected an extremely wide 202 
spectrum of distinct combinations. The number of regimens ranged from 40 regimens in CR Acinetobacter spp. To 203 
more than 100 regimens in CR Enterobacteriaceae. Ovrall, the combination “carbapenem plus a polymyxin” was 204 
the most prescribed option for treating sepsis, irrespective of bacterial species or sepsis source (full results on 205 
targeted treatment are presented in Figures S4a-c and T bles S11-S13).  206 
Only 80 responses were available regarding treatment options in children and neonates; similar to the adult 207 
population, the most commonly prescribed treatment among children was “carbapenem plus polymyxin”. Full data 208 
on pediatric population are available in the supplementary material (Table S14-S16). 209 
The concept of ‘combination therapy’ 210 
The main reasons leading to the prescription of combination treatment were to improve clinical efficacy (570/707; 211 
81% of respondents) and to reduce resistance developm nt (364/707; 51%) (Figure S5). According to 80% of 212 
respondents (611/783), ‘combination therapy’ must include antibiotics which retain some degree of in vitro activity 213 











(150/783) conceived ‘combination therapy’ as the simple association of two or more antibiotic compounds, 215 
regardless their potential in vitro activity (Table S17).  216 
Type of evidence supporting the use of combination herapy included: experts’ recommendations (62%; 486/777), 217 
evidence from randomized controlled trials (37%; 285/777), evidence from in vitro studies (36%; 277/777), 218 
controlled observational studies (34%; 264/777) and personal experience (29%; 224/777) (Figure S6).   219 
 220 
Discussion 221 
Our results showed that the treatment of CR-GNB infections  is far from being standardized and clinicians over the 222 
world use  a wide range of antibiotic strategies  and combinations depending on clinical severity, loca  availability 223 
and clinical experience. Of interest, empiric coverage for CR-GNB was driven mostly by the severity of the clinical 224 
scenario and more commonly prescribed in High-Income-Countries compared to lower resourced settings. As for 225 
targeted treatment, the majority of respondents opted for a double-antibiotic combination (most commonly 226 
polymyxin plus carbapenem) despite the lack of evidnce supporting this indication.  227 
Access to rapid diagnostics and recently approved antibiotics was inversely correlated with country economic status. 228 
Gentamicin, amikacin and TMP-SMX were the most accessible compounds worldwide, while new BL/BLIs and 229 
also older antibiotics such as colistin and polymyxin B were available in less than 50% of the surveyed countries. 230 
Our results confirmed that not only high-priced newer drugs are very rarely accessible, but also off-patent drugs can 231 
encounter supply shortages since manufacturing costs are not compensated by the low sale-price.(19) A survey 232 
conducted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) revealed that here 233 
was a reduction in access to ‘old antibiotics’ in the United States, Europe and Australia from 2011 to 2015.(20) 234 
Similar data collected in Lower-Middle-Income-Countries found that access to ‘old antibiotics’ was very limited 235 
even in countries with high rates of antibiotic resistance.(21) 236 
Up to 80% of respondents from High-Income-Countries favoured empirical coverage for CR-GNB in presence of 237 
severe clinical condition and epidemiological risk factors. Conversely, confronted with the same clinial scenario, 238 
only half of respondents from Lower-Middle-Income-Countries/Lower-Income-Countries opted for empirical 239 
coverage of CR-GNB. The main reason of this significant discrepancy probably resides in the lack of viable 240 
therapeutic options in those countries, in line with the most recent findings revealing that early coverage with 241 
colistin does not provide any benefit on survival in presence of severe CR-GNB infections.(22)  242 
As for targeted treatment, despite the overall preference for dual antibiotic therapy, a notable portion of prescribers 243 











monotherapy could either reflect the actual lack of evidence supporting specific combinations or the absence of 245 
other viable options due to concomitant resistance, drug toxicity or local unavailability.  246 
Despite the relatively low percentage of paediatricians and neonatologists contributing to the survey (8.5%), a 247 
significant heterogeneity of prescribing patterns was identified also in this patients’ population. A similar lack of 248 
standardization has been already observed in two global point prevalence surveys, where almost 200 different 249 
antibiotic regimens were used for treating sepsis in children and neonates.(23),(24) 250 
Overall, 80% of prescribers agreed that the main aim of combination therapy is to improve therapeutic efficacy, 251 
while 50% supported the use of combination for reducing resistance development or promoting microbiological 252 
eradication when compared to monotherapy. The majority f prescribers seemed to recognize that the use of 253 
combination therapy for treating CR-GNB infections comes from “expert” recommendations and that the supporting 254 
evidence is very poor and of low quality, being comp sed almost exclusively of observational and in vitro studies. 255 
Interestingly, approximately one third of respondents believed that the use of combination therapy is supported by 256 
RCTs, although valid examples in the literature are scarce.(25) A even much higher rate of prescribers sharing this 257 
same misconception have been also observed in a simil r survey on management of CR-GNB infections in Europe 258 
and US in 2017. In this study, up to 55% of respondents declared that combination therapy is supported by a strong 259 
level of evidence.(26)  260 
 261 
Finally, it is notable  that the concept of ‘combination therapy’ had a different meaning among respondents, with 262 
42% indicating ‘combination of in vitro active drugs’, 38% indicating ‘combination of in vitro synergistic drugs’ 263 
and 20% indicating ‘combination of two or more drugs, regardless the in vitro activity’. Disagreement among 264 
respondents clearly reflects the lack of a standardized definition for ‘combination therapy’ also in clinical studies, 265 
with the result that there can be a misinterpretation and poor generalizability of study results.(27) 266 
Although the referral process allowed the rapid recruitment of respondents from areas of the world that are usually 267 
difficult to access, the use of a non-probabilistic sampling method remains a main limitation of this study. Our 268 
sampling process started from surveillance networks in order to track and filter hospitals and countries having the 269 
minimum standard needed for diagnosing CR-GNB infections. Therefore, we may have missed countries and 270 
hospitals in which microbiological diagnosis is made with an acceptable degree of standardization, but without 271 
active surveillance systems, particularly in LMIC/LIC and non-English speaking countries. Additionally, it should 272 











than others, with risk of over-representing certain prescribers. For this reason, a post-stratification c rrection with 274 
inverse proportional weighting was applied to mitiga e the risk of oversampled countries and hospitals.  275 
In conclusion, we recorded a huge variability in the management of severe CR-GNB infections among overn -276 
thousand clinicians worldwide. Unequal access to diagnostic and therapeutic resources and the unavailability of 277 
evidence-based recommendations were two strong determinants contributing to this heterogeneity. Additionally, the 278 
lack of a universally accepted definition of ‘combination therapy’ might have further impaired the confidence in 279 
results from available clinical studies. These results demonstrate the urgent need for public health focussed strategic 280 
randomised controlled trials with the involvement of Low and Low-Middle-Income-Countries. International 281 
guidelines will be able to inform decision-making only when results from adequately conducted RCTs will be 282 
available.  283 
 284 
Role of the funding source  285 
GARDP supported the entire project, GARDP secondee (LJVP) and employees contributed to study design, data 286 
interpretation, and writing of the manuscript. All authors had full access to data and had final responsibility for the 287 
decision to submit for publication. 288 
 289 
Contributors 290 
ET and LJVP conceived the idea for this project. EC, AS, SE, FF, LJVP and ET designed the study. AS, EC, AG 291 
contributed to the data analysis and synthesis. AS and EC wrote the paper. All authors contributed to the survey 292 
development, pilot phase, revision of the paper and approval of the final version for submission. All authors had full 293 
access to all the data in the study and had final responsibility for the decision to submit for publication. 294 
 295 
Declaration of interests 296 
AS, EC, AG, GLH, ER, CT, AR, HZ, CG, AJB and ET have no competing interests to be declared. SE, FF and 297 
LJVP  are employed by GARDP.  PNAH declares research grants outside the submitted work from Sandoz, 298 
Shionogi and MSD and speakers’ fees from Pfizer. 299 
 300 
Acknowledgments 301 











We also thank each member of the COHERENCE core-exprt group: Mohammad Abdallah, Aaron Oladipo 303 
Aboderin, Akim Adegnika Ayola, Tara Anderson, Anucha Apisarnthanarak, Tobias Manuel Appel, Amin A. Aqel, 304 
Alexandra Barac, Nur Benzonana, Gabriel Birgand, Michael Borg, Eric Brown, Biljana Carević, Miquel 305 
Ekkelkamp, Karl Emerole, Maha Fathy, Fidelma Fitzparick, Nikkiah Forbes, Corey A. Forde, Alexander W.  306 
Friedrich, Ana Cristina Gales, Brent Gilpin, Christian Giske, Debra Goff, Eduardo Gotuzzo, Nelesh Govender, 307 
Manuel Guzman Blanco, Rahm Hamers, Patrick Harris, Po-Ren Hsueh,  Alain C. Juayan, Gunnar Kahlmeter, Souha 308 
Kanj, Basudha Khanal, Yang Soo Kim, Bela Kocsis, Roman Kozlov, Fiorella Krapp Lopez, Jaime Labarca, Todd 309 
Campbell Lee, Amel Omezzine Letaief,  Gabriel Levy Hara, Yi-Tsung Lin, Veranja Liyanapathirana, David 310 
Lupande, Surbhi Malhotra-Kumar, Kalisvar Marimuthu, Marc Mendelson,  Gordana Mijovic, Rima A. Moghnieh,  311 
Andreea Moldovan,  Jaime C. Montoya, Nico Mutters, Lawrence Mwananyanda, Aissatou Lakhe Ndeye, Jason 312 
Newland, Alison Nicholson, Ahmad Norazah Binti, Carlos Palos, Lea Papst, Aurelia Jennifer Perera, Pakpoom 313 
Phoompoung, Chimanjita Phukan, Elisabeth Presterl, Dianelys Quinones Perez, Lul Raka , Ossama Rasslan, E da 314 
Righi, Jesus Rodriguez Bano, Emmanuel Roilides, Bhattacharya Sanjay, Al-Abri Seif Salem, Sharmila Sengupta, 315 
Sadia Shakoor, Mike Sharland, Nalini Singh, Le Huu Song, Igor Stoma, Silva Tafaj,  Pierre Tattevin, Jens Thomsen, 316 
Athanasios Tsakris, David Tsibadze, Paul Turner, David Van Duin, Silvio Vega, Thirumalaisamy P Velavan, Aija 317 
Vilde, Maria Virginia Villegas, Peter Waiswa, Timothy Walsh, Minggui Wang, Evelyn Wesangula, Andreas F. 318 













1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and 322 
development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect 323 
Dis. 2018;18(3):318-27. 324 
2. Theuretzbacher U, Bush K, Harbarth S, Paul M, Rex JH, Tacconelli E, et al. Critical analysis of 325 
antibacterial agents in clinical development. Nat Rev Microbiol. 2020;18(5):286-98. 326 
3. Parchem NL, Bauer KA, Cook CH, Mangino JE, Jones CD, Porter K, et al. Colistin combination therapy 327 
improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia. Eur J Clin 328 
Microbiol Infect Dis. 2016;35(9):1433-9. 329 
4. Simsek F, Gedik H, Yildirmak MT, Iris NE, Turkmen A, Ersoy A, et al. Colistin against colistin-only-330 
susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy? Indian J Med 331 
Microbiol. 2012;30(4):448-52. 332 
5. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome f 333 
bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. 334 
Antimicrob Agents Chemother. 2012;56(4):2108-13. 335 
6. Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment of 336 
infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial 337 
Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob 338 
Chemother. 2018;73(suppl_3):iii2-iii78. 339 
7. Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of Infections Caused by 340 
Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol 341 
Rev. 2018;31(2). 342 
8. Isler B, Doi Y, Bonomo RA, Paterson DL. New Treatment Options against Carbapenem-Resistant 343 
Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2019;63(1). 344 
9. Sadler GR, Lee HC, Lim RS, Fullerton J. Recruitment of hard-to-reach population subgroups via 345 
adaptations of the snowball sampling strategy. Nurs Health Sci. 2010;12(3):369-74. 346 
10. Naderifar M. GH, Ghaljaie F. Snowball Sampling: A Purposeful Method of Sampling in Qualitative 347 
Research. Strides Dev Med Educ 2017;14. 348 
11. Atkinson R. FJ. Accessing Hidden and Hard-to-Reach Populations: Snowball Research Strategies. 2001. 349 
12. Colbert CY, Diaz-Guzman E, Myers JD, Arroliga AC. How to interpret surveys in medical research: a 350 
practical approach. Cleve Clin J Med. 2013;80(7):423-35. 351 
13. Kelley K, Clark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. Int J 352 
Qual Health Care. 2003;15(3):261-6. 353 
14. Bennett C, Khangura S, Brehaut JC, Graham ID, Moher D, Potter BK, et al. Reporting guidelines for 354 











15. Burns KE, Duffett M, Kho ME, Meade MO, Adhikari NK, Sinuff T, et al. A guide for the design and 356 
conduct of self-administered surveys of clinicians. Cmaj. 2008;179(3):245-52. 357 
16. Draugalis JR, Coons SJ, Plaza CM. Best practices for survey research reports: a synopsis for authors and 358 
reviewers. Am J Pharm Educ. 2008;72(1):11. 359 
17. Little RJA. Post-Stratification: A Modeler's Perspective. Journal of American Statistical Association. 360 
1993;88(423):1001-12. 361 
18. Williams IBaR. Post-stratification and Response Bias in Survey Data with Applications in Political Science. 362 
2005. 363 
19. Monnier AA, Schouten J, Tebano G, Zanichelli V, Huttner BD, Pulcini C, et al. Ensuring Antibiotic 364 
Development, Equitable Availability, and Responsible Use of Effective Antibiotics: Recommendations for 365 
Multisectoral Action. Clin Infect Dis. 2019;68(11):952-9. 366 
20. Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O. Forgotten antibiotics: a follow-up 367 
inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents. 2017;49(1):98-101. 368 
21. Tebano G, Li G, Beovic B, Bielicki J, Brink A, Enani MA, et al. Essential and forgotten antibiotics: An 369 
inventory in low- and middle-income countries. Int J Antimicrob Agents. 2019;54(3):273-82. 370 
22. Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, et al. The Association 371 
Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-372 
negative Bacteria: A Prospective Study. Clin Infect Dis. 2018;67(12):1815-23. 373 
23. Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R. Carbapenem-Resistant 374 
Enterobacteriaceae in Children, United States, 1999-2012. Emerg Infect Dis. 2015;21(11):2014-21. 375 
24. Jackson C, Hsia Y, Basmaci R, Bielicki J, Heath PT, Versporten A, et al. Global Divergence From World 376 
Health Organization Treatment Guidelines for Neonatal nd Pediatric Sepsis. The Pediatric Infectious Disease 377 
Journal. 2019;38(11). 378 
25. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus 379 
colistin plus meropenem for treatment of severe infctions caused by carbapenem-resistant Gram-negativ bacteria: 380 
an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391-400. 381 
26. Papst L, Beovic B, Pulcini C, Durante-Mangoni E, Rodriguez-Bano J, Kaye KS, et al. Antibiotic treament 382 
of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional 383 
survey among infectious diseases specialists practicing n large hospitals. Clin Microbiol Infect. 2018;24(10):1070-384 
6. 385 
27. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination 386 












Table 1: Number of respondents stratified by the four subgroups of interest 1 
WHO region Respondents, n (%) 
Africa 64 (6⋅0) 
Americas 205 (20⋅5)  
Eastern Mediterranean 116 (11⋅5) 
Europe 444 (44⋅0) 
South East Asia 95 (9⋅3) 
Western Pacific 88 (8⋅7) 
Total   1012 (100) 
Patients' age Respondents, n (%) 
Adults  867 (85⋅6) 
Pediatric population 145 (14⋅3) 
- Children    - 110 (10⋅9) 
- Neonates  - 35 (3⋅5) 
Total 1012 (100) 
Income category Respondents, n (%) 
High income countries 512 (50⋅6) 
Upper-Middle income countries  296 (29⋅2)  
Lower -Middle income/Low 
income countries 
204 (20⋅1) 
Total   1012 (100) 
Prescribing frequency*  Respondents, n (%) 
Low rate prescribers  257 (25⋅4) 
Medium rate prescribers  416 (41⋅1) 
High rate prescribers  283 (28⋅0) 
Not specified 56 (5⋅5) 
Total 1012 (100) 
*low rate prescribers: from 1 to 4 cases per year; medium rate 
prescribers: from 5 to 20 cases per year, high rate prescribers: 
more than 20 cases per year 















45⋅8 (N 469) 
UMIC  
26⋅3 (N 268) 
LMIC/LIC 




Standard AST  75⋅2 (373) 82⋅6 (238) 76⋅3 (156) 77⋅5 (767) NS 
MALDI-TOF  58⋅8 (277) 17⋅7 (61) 2⋅8 (15)  32⋅4 (353) <0⋅001 
Rapid phenotypic test from blood 
isolates  
32⋅3 (142) 21⋅1 (61) 1⋅5 (15)  20⋅8 (218) <0⋅001 
NAAT  47⋅2 (217) 15⋅4 (45) 9⋅6 (21) 28⋅4 (283) <0⋅001 
- in all CR-GNB strains 26⋅6 (157) 6⋅4 (16) 5⋅8 (11) 15⋅5 (184) <0⋅001 
- only in selected cases 20⋅6 (60) 9⋅1 (29) 3⋅7 (10)  12⋅9 (99) 0⋅008 
Internal testing facilities NOT 
available  
5⋅3 (34)  14⋅0 (38) 21⋅7 (25)  10⋅ 6 (97) <0⋅001 
Frequencies of positive responses are presented as percentages of the total of responses from each income 
category after adopting post-stratification correction by hospital and country; n: number of respondents. 
AST: Antimicrobial susceptibility test; NAAT: nucle ic acid amplification testing; NS: non-significant; HIC: 
High income countries, UMI: Upper-Middle income countries; Lower -Middle income/Low income countries 











Table 3: Time needed by laboratories to inform on the positivity of blood cultures 5 
Time to positive 
blood cultures 
Income category 
% (n) of country 
P value 
HIC  
51⋅5 (N 500) 
UMI 
27⋅2 (N 282) 
LMI/LIC 
25⋅3 (N 191) 
Within 36 hours 41⋅2 (172) 21⋅6 (70) 20⋅8 (51) 0⋅01 
Within 48 hours* 73⋅2 (349) 40⋅0 (139) 42⋅5 (93) <0⋅001 
Within 72 hours* 80⋅1 (463) 52⋅0 (224) 59⋅8 (139) <0⋅001 
Within 96 hours* 99⋅1 (494) 91⋅8 (260) 80⋅4 (174) <0⋅001 
More than 96 hours 0⋅9 (6) 8⋅2 (22) 19⋅6 (17) <0⋅001 
Frequencies of positive responses are presented as cumulative percentages within each time interval using the 
total of responses from each income category as a denominator and applying post-stratification correction by 
hospital and country; HIC: High Income countries, UMI: Upper-Middle income countries; Lower -Middle 
income/Low income countries 























Plazomicin Eravacycline Aztreonam 
N (%) C/A (%) C/A (%) C/A (%) C/A (%) C/A (%) C/A (%) 
High rate 
prescriber 
11/255 (4.3) 0/4 (0) 39/86 (45.3) 26/93 (28.0) 1/3 (33.3) 0/2  28/100  (28.0 
Medium rate 
prescriber 
29/321 (9.0) 7/19 (36.8) 72/146 (49.3) 47/151 (31.1) 0/3 (0.0) 0/4  37/139 (26.6) 
Low rate 
prescriber 
68/209 (32.5) 4/23 (17.4) 34/101 (33.7) 21/100 (21.0) 2/6 (33.3) 2/6 (33.3) 24/117 (20.5) 
Overall 108/785 (13.7) 11/46 (23.9) 145/333 (45.3) 94/344 (27.3) 3/12 (25) 2/12 (16.7) 89/356 (25) 
P value <0.001  NP  0.047  NP  NP  NP NP 
Prescribing 
frequency 
Gentamicin Tobramycin Amikacin Tigecycline Polymyxin B Colistin 
Fosfomycin 
(IV) 
C/A (%) C/A (%) C/A (%) C/A (%) C/A (%) C/A (%) C/A (%) 
High rate 
prescriber 












74/205 (36.1) 37/137 (27.0) 102/187 (54.5) 137/156 (87.8) 18/77 (23.4) 89/160 (55.6) 41/113 (36.3) 
Overall 264/770 (34.2) 80/445 (17.9) 394/742 (53) 330/647 (70.6) 104/297 (35) 492/671 (73) 244/463 (52.7) 
P value NP  0.004  NP <0.001 0.009  <0.001 <0.001 
Legend: C: always in combination; A: number of respondents with available agent; NP: not performed (less than five respondents contributed to the 
analysis) 
The results are presented as proportions and stratified by prescribing frequency. As denominator, only the number of respondents declaring the 
availability of the antibiotic compounds were considered. The statistical significance was computed only if more than five respondents contributed to 
the analysis.  
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Figure 1: Percentage of respondents who are likely to cover empirically for CR-GNB according to different 10 
clinical, epidemiological/microbiological factors and stratified by country-income 11 
12 
(%) OF RESPONDENTS 
CLINICAL FACTORS 
Clinically stable/ 
No risk factor for 
immunodepression 
Clinically stable/ 











































in ANY site 
HIC 8⋅1 32⋅7 80⋅6 70⋅2 
UMIC 4⋅3 26⋅4 66⋅6 63⋅4 
LMIC/LIC 2⋅3 35⋅5 50⋅1 43⋅7 








HIC 28⋅0 55⋅0 83⋅1 67⋅9 
UMIC 14⋅8 46⋅9 74⋅1 62⋅8 
LMIC/LIC 26⋅9 36⋅0 40⋅6 42⋅6 







HIC 7⋅6 64⋅3 67⋅2 66⋅8 
UMIC 6⋅3 29⋅8 65⋅7 62⋅7 
LMIC/LIC 6⋅0 38⋅7 49⋅1 36⋅4 






HIC 4⋅7 26⋅2 58⋅7 57⋅1 
UMIC 4⋅6 18⋅3 62⋅1 58⋅7 
LMIC/LIC 9⋅3 18⋅2 43⋅7 31⋅1 





HIC 5⋅9 23⋅0 56⋅0 55⋅3 
UMIC 5⋅4 27⋅2 66⋅4 50⋅1 
LMIC/LIC 3⋅9 15⋅8 44⋅0 61⋅3 






HIC 25⋅6 60⋅5 81⋅0 70⋅5 
UMIC 24⋅8 45⋅9 81⋅2 70⋅9 
LMIC/LIC 13⋅2 46⋅7 58⋅0 41⋅0 






carba-NP*   
HIC 54⋅6 68⋅3 63⋅5 62⋅7 
UMIC 30⋅9 53⋅6 67⋅4 65⋅5 
LMIC/LIC 0⋅0 30⋅4 69⋅5 54⋅3 
p value NS NS NS NS 
Abbreviations: HIC: high income countries; UMIC: upper-middle income countries; LMIC: lower-middle income 
countries; LIC: low income countries; NAAT: nucleic acid amplification testing; NS: not statistically significant.  
*Number of respondents for denominator are 215 (only the respondents declaring that their labs can perform rapid 
tests for CR-GNB). 
The results are presented as weighted proportions after adopting post-stratification correction according to hospital 
and country. The likelihood of empiric coverage for CR-GNB is divided into four thresholds and graphically 
represented according to this color scale:  
Jo
urn
al 
Pr
e-p
roo
f
 
6 
 
 
Jo
urn
al 
Pr
e-p
roo
f
